Effect of anakinra on arthropathy in CINCA/NOMID syndrome by Miyamae, Takako et al.
CASE REPORT Open Access
Effect of anakinra on arthropathy in CINCA/
NOMID syndrome
Takako Miyamae
1*, Yutaka Inaba
2, Gen Nishimura
3, Masako Kikuchi
1, Takayuki Kishi
1, Ryoki Hara
1, Utako Kaneko
1,
Toshihiko Shinoki
1, Tomoyuki Imagawa
1, Shumpei Yokokta
1
Abstract
CINCA/NOMID is an autoinflammatory disorder characterized by the triad of neonatal onset of cutaneous symp-
toms, chronic meningitis, and recurrent fever and it presents with distinctive osteoarthropathy, synovitis mainly of
the large joints and overgrowth of epimetaphyseal cartilage, particularly of the long bones. The cartilage over-
growth eventually causes osseous overgrowth and deformity that persists beyond skeletal maturity and leads to
limb length discrepancy, joint contracture, and early degenerative arthropathy. Autoinflammation in CAPS/NOMID
has been proven to derive from excessive release of interleukin-1 (IL-1). It has been well documented that the IL-1
receptor antagonist anakinra (Kineret(R)) helps mitigate systemic inflammation in the disorder. However, a general
consensus has not been reached on its beneficial effect on osteoarthropathy. The case of a girl with CINCA/NOMID
syndrome who showed dramatic improvement of osteoarthropathy after anakinra treatment is reported. A 4-year-
old girl suffered at the age of 10 months from a generalized urticarial skin lesion with recurrent episodes of fever
and growth disorder. Blood examination revealed persistent massive neutrophilia, anemia and intense acute phase
response. She manifested knee joint swelling with limited ROM when she was 20 months old and was diagnosed
as being CINCA/NOMID based on characteristic findings of radiograph despite negative CIAS1 mutation. Radiologi-
cal examination demonstrated metaphyseal fraying and cupping and widening of the growth plate in the distal
femur. MR imaging showed mottled gadolinium enhancement at the chondrosseous junction. Neither significant
joint effusion nor synovitis was identified. At 2 years and 7 months of age, anakinra, 2 mg/kg/day given by regular
daily subcutaneous injections, was started. A few days after the initiation of the treatment, her clinical symptoms
and laboratory findings of active inflammation were promptly alleviated. She was not able to walk unaided prior to
the treatment, but she walked independently 1 month after the treatment. Follow-up radiographs and MR imaging
showed that growth plate widening and gadolinium enhancement at the chondrosseous junction were less con-
spicuous. Furthermore, longitudinal growth of the femur and tibia was identified during 20 months of observation.
Background
CINCA/NOMID is an autoinflammatory disorder char-
acterized by the triad of neonatal onset of cutaneous
symptoms, chronic meningitis, and recurrent fever [1-4]
Since many cases are attributed to heterozygous gain-of-
function mutations in NLRP3 (CAIS1), the gene encoding
cryopyrin [5,6], it is classified into cryopyrin-associated
periodic syndromes (CAPS). CAPS include three allelic
variants, ranging in order of increasing severity from
Familial Cold Auto-inflammatory Syndrome (FCAS), pre-
viously termed Familial Cold Urticaria, through Muckle-
Wells Syndrome (MWS) to Chronic Infantile Neurologic
Cutaneous Articular Syndrome or Neonatal-Onset Multi-
system Inflammatory Disease (CINCA/NOMID) [7,8].
However, CINCA/NOMID may be heterogeneous, and
only 60% of affected individuals have NLRP3 mutations.
CINCA/NOMID presents with distinctive osteoarthro-
pathy, mainly of the large joints and overgrowth of epi-
metaphyseal cartilage, particularly of the long bones.
Histological examination for overgrown cartilage shows
complete disorganization of the cartilage cell columns
and irregular metachromasia of the cartilage substance,
but no inflammatory cell infiltrates [4]. The cartilage
overgrowth eventually causes osseous overgrowth and
deformity that persists beyond skeletal maturity
and leads to limb length discrepancy, joint contracture,
and early degenerative arthropathy [3,9,10] In particular,
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femur is so characteristic that its presence warrants a
diagnosis of CINCA/NOMID.
Autoinflammation in CAPS has been proven to derive
from excessive release of interleukin-1b (IL-1b) [11].
Interestingly, deficiency of the IL-1 receptor antagonist
due to mutations of IL1RN gives rise to the phenotype
sharing some features with CINCA/NOMID but with
some clinical peculiarities regarding skin and bone man-
ifestations [12]. It has been well documented that the
IL-1 receptor antagonist anakinra (Kineret®) helps miti-
gate systemic inflammation in both disorders [12-14].
However, a general consensus has not been reached on
its beneficial effect on osteoarthropathy. The case of a
girl with CINCA/NOMID syndrome who showed dra-
matic improvement of overgrowth osteoarthropathy
after anakinra treatment is reported.
Case presentation
The girl was born by normal vaginal delivery following an
unremarkable pregnancy. The parents were healthy and
nonconsanguineous. At 10 months of age, the girl pre-
sented with recurrent episodes of fever and growth disor-
der associated with a generalized, maculopapular,
urticaria-like skin rash. Blood examination revealed mas-
sive neutrophilia, anemia, and intensely elevated acute
phase reactants. Antibiotic treatment failed to alleviate the
clinical symptoms. At 20 months of age, she developed
knee joint swelling with limited ROM resulting in pro-
blems with standing and walking. Radiological examina-
tion demonstrated metaphyseal fraying and cupping and
widening of the growth plate in the distal femur (Figure 1).
MR imaging showed mottled gadolinium enhancement at
the chondrosseous junction (Figure 2). Neither significant
joint effusion nor synovitis was identified. She was diag-
nosed as having CINCA/NOMID on clinical and radiologi-
cal grounds; however, analysis of cerebrospinal fluid (CSF)
showed neither pleocytosis nor increased protein levels, and
a molecular examination did not show NARLP3 mutations.
At 2 years and 7 months of age, anakinra, 2 mg/kg/day
given by regular daily subcutaneous injections, was started.
A few days after the initiation of the treatment, her consti-
tutional symptoms, fever and urticaria-like rash, and acute-
phase reactant levels were promptly alleviated. She was not
able to walk unaided prior to the treatment, but she walked
independently 1 month after the treatment. Follow-up
radiographs and MR imaging (Figure 3) showed that
growth plate widening and gadolinium enhancement at the
chondrosseous junction were less conspicuous.
Furthermore, longitudinal growth of the femur and tibia
was identified during 20 months of observation (Data not
shown).
Figure 1 Radiographs at 24 months of age. (A: frontal view of the lower extremities, B: lateral view of the right knee, C: lateral view of the left
knee) show metaphyseal fraying and cupping and widening of the growth plate in the distal femur (arrow).
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Although no NARLP3 mutations were found in the
present case, a diagnosis of CINCA/NOMID was war-
ranted on clinical and radiological grounds. Her der-
matological manifestation differed from that of
deficiency of the IL-1 receptor antagonist (urticaria-
like skin rash vs. pyoderma). Her clinical and radiologi-
cal evolution following anakinra treatment implied that
the therapy was effective not only in mitigating clinical
symptoms of autoinflammation but also in preventing
progression of osteoarthropathy. The beneficial effect
of anakinra on arthropathy has been controversial.
Figure 2 Sagittal MR images and lateral radiograph of the left knee at 2 years and 7 months of age, prior to introduction of anakinra.
(A: MRI T1-weighted, B: MRI T2-weighted, C MRI T1-weighted with fat suppression and gadolinium-enhancement, D radiograph): T1- and T2-
weighted MR images show widening of the growth plate (arrow 1), and a gadolinium-enhanced MR image shows mottled enhancement at the
chondroosseous junction (arrow 2).
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anakinra was initiated, the better arthropathy was over-
come. If the treatment had not been introduced, the
osteoarthropathy eventually would have led to severe
joint deformations, limb length discrepancy, and
growth retardation, as previously reported. Once bone
deformations develop in patients with CINCA/
NOMID, they are very difficult to reverse [14]. How-
ever, the tragic consequences can be prevented by
early medical intervention in this case.
The imaging findings in the present girl included widen-
ing of the growth plate and gadolinium enhancement at
Figure 3 MR images and radiograph of the left knee at the age of 4 years and 3 months, after more than 20 months of anakinra
treatment. (MRI A: T1-weighted, B: MRI T2-weighted, C: MRI T1-weighted with fat suppression and Ga enhancement, D radiograph). The growth
plate widening previously seen (Figure 2) has alleviated with anakinra treatment. A gadolinium-enhanced MR image demonstrates less
conspicuous enhancement at the chondroosseous junction after the anakinra treatment.
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sense termed ‘’metaphyseal dysplasia’’, and are consistent
with the known histological findings in CINCA/NOMID.
According to a previous report, the histological findings
for biopsy specimens from a ‘’bony mass’’ were 1) disorga-
nized cartilage at the growth plate and 2) thin metaphyseal
trabeculae mixed with relatively acellular cartilage, fibrous
tissues, and foci of calcification [10] The latter finding may
correspond with gadolinium enhancement of the chon-
drosseous junction. In the present case, the anakinra treat-
ment provided remodeling of the ‘’metaphyseal dysplasia’’
with alleviation of gadolinium enhancement. This fact sug-
gests that osteoarthropathy in CINCA/NOMID is caused
by overproduction of IL-1b, as are the symptoms of auto-
inflammation and disappearance of them by specific
receptor antagonist of IL-1b.
Osteoarthropathy is significant in approximately 60%
of CINCA/NOMID patients, and it is more prevalent in
cases with deficiency of the IL-1 receptor antagonist.
The mechanism to explain why the excessive production
of IL-1b causes distinctive osteocartilaginous overgrowth
in CINCA/NOMID still remains unclear. Though it has
been reported that IL-1b exerts inhibitory effects on
murine ATDC5 chondrocyte dynamics and metatarsal
longitudinal growth [15], recent observation suggested
that overgrowth arthropathy in CINCA/NOMID is not
driven by IL-1b, but such overgrowth may be due to
abnormal apoptosis at the site of enchondral ossification
as NALP3 is expressed in cartilage [16,17].
Conclusion
This report indicated the importance of earlier indica-
tion of anakinra for better outcome of arthropathy in
CINCA/NOMID syndrome. Once once bone deforma-
tions develop in the patients, they are very difficult to
reverse even with anakinra.
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